

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai Haohai Biological Technology Co., Ltd.*

上海昊海生物科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6826)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made by Shanghai Haohai Biological Technology Co., Ltd.* (the “**Company**”) pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Reference is made to the announcement of the Company dated 18 April 2019 on the acceptance by the Shanghai Stock Exchange of application materials for the proposed A share offering of the Company (the “**A Share Offering**”), and the overseas regulatory announcements of the Company dated 16 May 2019, 28 May 2019 and 4 June 2019, respectively.

The Company received the Letter of Implementation for the Opinion of the Audit Center on Shanghai Haohai Biological Technology Co., Ltd.’s Initial Public Offering and Listing on the Sci-Tech Innovation Board (《關於上海昊海生物科技股份有限公司首次公開發行股票並在科創板上市的審核中心意見落實函》) from the Shanghai Stock Exchange on 3 July 2019 (the “**Letter of Implementation**”). In response to the Letter of Implementation, the Company has submitted the Response to the Letter of Implementation for the Opinion of the Audit Center on Shanghai Haohai Biological Technology Co., Ltd.’s Initial Public Offering and Listing on the Sci-Tech Innovation Board (《關於上海昊海生物科技股份有限公司首次公開發行股票並在科創板上市的審核中心的意見落實函的回覆》) (the “**Response**”) to the Shanghai Stock Exchange. The Response and related materials have been published on the website of the Review and Approval of the Issuance of Listing of Stocks on the Sci-Tech Innovation Board of the Shanghai Stock Exchange (上海證券交易所科創板股票發行上市審核網站) at kcb.sse.com.cn on 4 July 2019.

As the A Share Offering is subject to certain conditions precedent, it may or may not proceed to completion and the shareholders and potential investors of the Company are advised to exercise caution when dealing in the H shares of the Company. Further announcement(s) will be published by the Company as and when appropriate in respect of any material development relating to the A Share Offering.

By order of the Board
Shanghai Haohai Biological Technology Co., Ltd.*
Chairman
Hou Yongtai

Shanghai, the PRC, 4 July 2019

As at the date of this announcement, the executive directors of the Company are Dr. Hou Yongtai, Mr. Wu Jianying, Mr. Huang Ming, Ms. Chen Yiyi and Mr. Tang Minjie; the non-executive director of the Company is Ms. You Jie; and the independent non-executive directors of the Company are Mr. Chen Huabin, Mr. Shen Hongbo, Mr. Zhu Qin and Mr. Wong Kwan Kit.

* For identification purpose only